Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ozan Cemal Içaçan"'
Publikováno v:
European Journal of Rheumatology, Vol 9, Iss 3, Pp 176-179 (2022)
Externí odkaz:
https://doaj.org/article/67e42af554394f1dbb17d6d80680317a
Publikováno v:
Clinical rheumatology. 41(5)
The most common cutaneous manifestation of small vessel vasculitis is palpable purpura. Etiology includes various causes such as infections, malignancies, drugs, and systemic vasculitides. The number of studies that evaluated the etiology of patients
Publikováno v:
La Clinica terapeutica. 172(5)
Pulmonary Alveolar Proteinosis (PAP) is a rare lung disease characterized by accumulation of a lipoproteinous material in the alveoli and distal airways. Antibodies against granulocyte macropha-ge colony stimulant factor (GM-CSF) are thought to be re
Autor:
Mustafa Çakan, Nuray Aktay Ayaz, Cemal Bes, Ayşe Tanatar, Selda Çelik, Figen Çakmak, Nilüfer Alpay Kanıtez, Şerife Gül Karadağ, Ozan Cemal İçaçan, Hafize Emine Sönmez
Publikováno v:
Poster Presentations.
Background Familial Mediterranean fever (FMF) is an autosomal recessively inherited autoinflammatory disease and begins in childhood. In nearly 60% of patients, the first attack occurs before the age of 10, and in 90% of them before the age of 20 yea
Publikováno v:
Annals of the Rheumatic Diseases. 79:1530.1-1530
Background:Purpura are lesions that occur after bleeding on the skin, mucous or serosal surfaces. Purpura can be classified into 2 subgroups; which are linked to thrombocytopenia and non-trombocytopenic purpura. While thrombocytopenic purpura often o
Autor:
Nilüfer, Alpay-Kanitez, Selda, Çelik, Feyyaz, Baltacioğlu, Ozan Cemal, Içaçan, Cemal, Bes, Bedrettin, Yildizeli
Publikováno v:
Clinical and experimental rheumatology. 37(6)
Autor:
Sinem Nihal Esatoglu, Koray Tascilar, Hakan Babaoğlu, Cemal Bes, Berna Yurttas, Servet Akar, Ozlem Pehlivan, Cansu Akleylek, Duygu Tecer, Emire Seyahi, Tuba Yuce-Inel, Nilufer Alpay-Kanitez, Erdal Bodakci, Emre Tekgoz, Seda Colak, Ertugrul Cagri Bolek, Suleyman Serdar Koca, Umut Kalyoncu, Ozan Cemal Icacan, Serdal Ugurlu, Hande Ece Oz, Vedat Hamuryudan, Gulen Hatemi, the Turkish Society for Rheumatology COVID-19 Registry Investigators, Ayse Cefle, Ali Karakas, Derya Kaskari, Samet Karahan, Dilek Tezcan, Abdurrahman Tufan, Ayse Ayan, Levent Kılıc, Salim Donmez, Mustafa Erdogan, Veli Yazisiz, Edip Gokalp Gok, Ahmet Eftal Yucel, Elif Dincses Nas, Gezmiş Kimyon, Gunay Sahin Dalgic, Hakan Erdem, Kerem Yigit Abacar, Ridvan Mercan, Omer Karadag, Onay Gercik, Suleyman Ozbek, Sebnem Gider, Semih Gulle, Sibel Osken, Sedat Kiraz, Timucin Kasifoglu, Fatma Alibaz-Oner, Izzet Fresko, Ali Akdogan, Neslihan Yilmaz
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThe course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used
Externí odkaz:
https://doaj.org/article/4de36d4dba664dd2ae34873a6dca683e